Deqiang An

Title: Deqiang An: Innovator in Antibody-Drug Conjugates

Introduction

Deqiang An is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of antibody-drug conjugates. With a total of six patents to his name, his work is paving the way for advancements in targeted therapies.

Latest Patents

One of Deqiang An's latest patents is focused on anti-CD79b antibodies, drug conjugates, and their applications. This patent discloses an anti-CD79b antibody or an antigen-binding fragment, which includes specific amino acid sequences that enhance its efficacy. Another notable patent involves tetramaleimide linkers, which are crucial for the preparation of antibody-drug conjugates. These linkers provide high homogeneity and stability, making them effective for treating various diseases, including tumors.

Career Highlights

Deqiang An is currently associated with Newbio Therapeutics, Inc., where he continues to innovate in the field of drug development. His expertise in antibody engineering and drug conjugation has positioned him as a key player in the biotechnology sector.

Collaborations

Deqiang An collaborates with talented individuals such as Nianhe Han and Chun Yang, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Deqiang An's work in the field of biotechnology, particularly in antibody-drug conjugates, showcases his commitment to advancing medical science. His patents reflect a deep understanding of the complexities of drug development, and his collaborations further enhance the potential for groundbreaking discoveries.